{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:44:44Z","timestamp":1791895484816,"version":"4.3.4"},"reference-count":30,"publisher":"Rockefeller University Press","issue":"8","content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,7,27]]},"abstract":"<jats:p>Plasmodium falciparum is the parasite responsible for the most lethal form of malaria, an infectious disease that causes a large proportion of childhood deaths and poses a significant barrier to socioeconomic development in many countries. Although antimalarial drugs exist, the repeated emergence and spread of drug-resistant parasites limit their useful lifespan. An alternative strategy that could limit the evolution of drug-resistant parasites is to target host factors that are essential and universally required for parasite growth. Host-targeted therapeutics have been successfully applied in other infectious diseases but have never been attempted for malaria. Here, we report the development of a recombinant chimeric antibody (Ab-1) against basigin, an erythrocyte receptor necessary for parasite invasion as a putative antimalarial therapeutic. Ab-1 inhibited the PfRH5-basigin interaction and potently blocked erythrocyte invasion by all parasite strains tested. Importantly, Ab-1 rapidly cleared an established P. falciparum blood-stage infection with no overt toxicity in an in vivo infection model. Collectively, our data demonstrate that antibodies or other therapeutics targeting host basigin could be an effective treatment for patients infected with multi-drug resistant P. falciparum.<\/jats:p>","DOI":"10.1084\/jem.20150032","type":"journal-article","created":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T01:54:43Z","timestamp":1437443683000},"page":"1145-1151","update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":71,"title":["Basigin is a druggable target for host-oriented antimalarial interventions"],"prefix":"10.1084","volume":"212","author":[{"given":"Zenon A.","family":"Zenonos","sequence":"first","affiliation":[{"name":"Cell Surface Signalling Laboratory 1 and 2"},{"name":"Malaria Program, Wellcome Trust Sanger Institute, Cambridge CB10 2DP, England, UK 1 and 2"},{"name":"Cell Surface Signalling Laboratory 1 and 2"},{"name":"Malaria Program, Wellcome Trust Sanger Institute, Cambridge CB10 2DP, England, UK 1 and 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara K.","family":"Dummler","sequence":"additional","affiliation":[{"name":"SMART Singapore-MIT-Alliance for Research and Technology, Infectious Disease IRG, Singapore 138602, Singapore 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"M\u00fcller-Sienerth","sequence":"additional","affiliation":[{"name":"Cell Surface Signalling Laboratory 1 and 2"},{"name":"Malaria Program, Wellcome Trust Sanger Institute, Cambridge CB10 2DP, England, UK 1 and 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhu","family":"Chen","sequence":"additional","affiliation":[{"name":"SMART Singapore-MIT-Alliance for Research and Technology, Infectious Disease IRG, Singapore 138602, Singapore 3"},{"name":"Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02420 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Preiser","sequence":"additional","affiliation":[{"name":"SMART Singapore-MIT-Alliance for Research and Technology, Infectious Disease IRG, Singapore 138602, Singapore 3"},{"name":"Nanyang Technological University, School of Biological Sciences, Singapore 637551, Singapore 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian C.","family":"Rayner","sequence":"additional","affiliation":[{"name":"Cell Surface Signalling Laboratory 1 and 2"},{"name":"Malaria Program, Wellcome Trust Sanger Institute, Cambridge CB10 2DP, England, UK 1 and 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin J.","family":"Wright","sequence":"additional","affiliation":[{"name":"Cell Surface Signalling Laboratory 1 and 2"},{"name":"Malaria Program, Wellcome Trust Sanger Institute, Cambridge CB10 2DP, England, UK 1 and 2"},{"name":"Cell Surface Signalling Laboratory 1 and 2"},{"name":"Malaria Program, Wellcome Trust Sanger Institute, Cambridge CB10 2DP, England, UK 1 and 2"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2015,7,20]]},"reference":[{"key":"2023072602595246000_bib1","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/jac\/dkq261","article-title":"Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection","volume":"65","author":"Bruno","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"2023072602595246000_bib2","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1101\/gr.7187808","article-title":"Large-scale screening for novel low-affinity extracellular protein interactions","volume":"18","author":"Bushell","year":"2008","journal-title":"Genome Res."},{"key":"2023072602595246000_bib3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ijrobp.2005.12.034","article-title":"Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I\/II trials","volume":"65","author":"Chen","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2023072602595246000_bib4","doi-asserted-by":"publisher","first-page":"e1002199","DOI":"10.1371\/journal.ppat.1002199","article-title":"An EGF-like protein forms a complex with PfRh5 and is required for invasion of human erythrocytes by Plasmodium falciparum","volume":"7","author":"Chen","year":"2011","journal-title":"PLoS Pathog."},{"key":"2023072602595246000_bib5","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1073\/pnas.1323318111","article-title":"Human natural killer cells control Plasmodium falciparum infection by eliminating infected red blood cells","volume":"111","author":"Chen","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023072602595246000_bib6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fmicb.2014.00314","article-title":"Association of antibodies to Plasmodium falciparum reticulocyte binding protein homolog 5 with protection from clinical malaria","volume":"5","author":"Chiu","year":"2014","journal-title":"Front Microbiol."},{"key":"2023072602595246000_bib7","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/nature10606","article-title":"Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum","volume":"480","author":"Crosnier","year":"2011","journal-title":"Nature."},{"key":"2023072602595246000_bib8","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1182\/blood.V98.7.2052","article-title":"Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL","volume":"98","author":"Deeg","year":"2001","journal-title":"Blood."},{"key":"2023072602595246000_bib9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4049\/jimmunol.1302045","article-title":"Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5","volume":"192","author":"Douglas","year":"2014","journal-title":"J. Immunol."},{"key":"2023072602595246000_bib10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.chom.2014.11.017","article-title":"A PfRH5-based vaccine is efficacious against Heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys","volume":"17","author":"Douglas","year":"2015","journal-title":"Cell Host Microbe."},{"key":"2023072602595246000_bib11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1182\/blood-2013-02-481887","article-title":"Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteers","volume":"122","author":"Ghevaert","year":"2013","journal-title":"Blood."},{"key":"2023072602595246000_bib12","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(95)91621-0","article-title":"Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1","volume":"346","author":"Heslop","year":"1995","journal-title":"Lancet."},{"key":"2023072602595246000_bib13","doi-asserted-by":"publisher","first-page":"11943","DOI":"10.1128\/JVI.79.18.11943-11951.2005","article-title":"The Src family kinase c-Yes is required for maturation of West Nile virus particles","volume":"79","author":"Hirsch","year":"2005","journal-title":"J. Virol."},{"key":"2023072602595246000_bib14","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1128\/AAC.00086-10","article-title":"Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults","volume":"54","author":"Jacobson","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"2023072602595246000_bib15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/intimm\/11.5.777","article-title":"T cell activation-associated epitopes of CD147 in regulation of the T cell response, and their definition by antibody affinity and antigen density","volume":"11","author":"Koch","year":"1999","journal-title":"Int. Immunol."},{"key":"2023072602595246000_bib16","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/S0149-2918(08)80048-3","article-title":"Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection","volume":"30","author":"Lieberman-Blum","year":"2008","journal-title":"Clin. Ther."},{"key":"2023072602595246000_bib17","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1182\/blood-2006-08-013995","article-title":"A phase 2\/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease","volume":"109","author":"Macmillan","year":"2007","journal-title":"Blood."},{"key":"2023072602595246000_bib18","first-page":"319","article-title":"The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding","volume":"86","author":"Morgan","year":"1995","journal-title":"Immunology."},{"key":"2023072602595246000_bib19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.cell.2013.02.027","article-title":"The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza","volume":"153","author":"Morita","year":"2013","journal-title":"Cell."},{"key":"2023072602595246000_bib20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/1475-2875-13-326","article-title":"A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein","volume":"13","author":"Ord","year":"2014","journal-title":"Malar. J."},{"key":"2023072602595246000_bib21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2174\/138161213804070276","article-title":"Targeting host factors to circumvent anti-malarial drug resistance","volume":"19","author":"Prud\u00eancio","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"2023072602595246000_bib22","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.3390\/ijms12064027","article-title":"Systematic approaches towards the development of host-directed antiviral therapeutics","volume":"12","author":"Prussia","year":"2011","journal-title":"Int. J. Mol. Sci."},{"key":"2023072602595246000_bib23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature."},{"key":"2023072602595246000_bib24","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1073\/pnas.1415466112","article-title":"Multiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial for Plasmodium falciparum erythrocyte invasion","volume":"112","author":"Reddy","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023072602595246000_bib25","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nm1265","article-title":"Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases","volume":"11","author":"Reeves","year":"2005","journal-title":"Nat. Med."},{"key":"2023072602595246000_bib26","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(83)91212-6","article-title":"Reversal of transplant rejection by monoclonal antiblast antibody","volume":"2","author":"Takahashi","year":"1983","journal-title":"Lancet."},{"key":"2023072602595246000_bib27","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1093\/infdis\/jit553","article-title":"Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria","volume":"209","author":"Tran","year":"2014","journal-title":"J. Infect. Dis."},{"key":"2023072602595246000_bib28","doi-asserted-by":"publisher","first-page":"20735","DOI":"10.1073\/pnas.1320771110","article-title":"RH5-Basigin interaction plays a major role in the host tropism of Plasmodium falciparum","volume":"110","author":"Wanaguru","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023072602595246000_bib29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature13715","article-title":"Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies","volume":"515","author":"Wright","year":"2014","journal-title":"Nature."},{"key":"2023072602595246000_bib30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/hep.21465","article-title":"A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation","volume":"45","author":"Xu","year":"2007","journal-title":"Hepatology."}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/212\/8\/1145\/1753446\/jem_20150032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/212\/8\/1145\/1753446\/jem_20150032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T03:00:18Z","timestamp":1690340418000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/212\/8\/1145\/41894\/Basigin-is-a-druggable-target-for-host-oriented"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,20]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,7,27]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20150032","relation":{},"ISSN":["1540-9538","0022-1007"],"issn-type":[{"value":"1540-9538","type":"electronic"},{"value":"0022-1007","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7,20]]}}}